omicron7 Dec 2021 20:43
British pharmaceutical giant GlaxoSmithKline says it has developed a coronavirus drug that is effective against all mutations of the Omicron variant.
GSK said its treatment, Xevudy (or sotrovimab), an antibody-based COVID-19 therapy, works against all 37 identified mutations to date in Omicron’s spike protein.
The data from early-stage studies is yet to be published in a peer-reviewed medical journal.